These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18647474)

  • 1. A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients.
    D'Avolio A; Sciandra M; Siccardi M; Baietto L; Gonzalez de Requena D; Bonora S; Di Perri G
    J Chromatogr Sci; 2008 Jul; 46(6):524-8. PubMed ID: 18647474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective determination of antiretroviral agents tenofovir, emtricitabine, and lamivudine in human plasma by a LC-MS-MS method for a bioequivalence study in healthy Indian subjects.
    Yadav M; Singhal P; Goswami S; Pande UC; Sanyal M; Shrivastav PS
    J Chromatogr Sci; 2010 Oct; 48(9):704-13. PubMed ID: 20875231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards.
    Delahunty T; Bushman L; Robbins B; Fletcher CV
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(20-21):1907-14. PubMed ID: 19493710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry.
    Nirogi R; Bhyrapuneni G; Kandikere V; Mudigonda K; Komarneni P; Aleti R; Mukkanti K
    Biomed Chromatogr; 2009 Apr; 23(4):371-81. PubMed ID: 18937306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.
    de Lastours V; Fonsart J; Burlacu R; Gourmel B; Molina JM
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4905-7. PubMed ID: 21788466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an LC-MS method for measuring TNF in human vaginal tissue.
    Choi SO; Rezk N; Kim JS; Kashuba AD
    J Chromatogr Sci; 2010 Mar; 48(3):219-23. PubMed ID: 20223089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of intracellular tenofovir-diphosphate and emtricitabine-triphosphate concentrations in dried blood spots for pre-exposure prophylaxis adherence.
    Tsuchiya K; Hayashi Y; Ryu S; Tran HT; Takano M; Tanaka K; Mizushima D; Oka S; Gatanaga H; Hamada A
    J Infect Chemother; 2024 Sep; 30(9):876-880. PubMed ID: 38431219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
    Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD
    J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry.
    Kromdijk W; Pereira SA; Rosing H; Mulder JW; Beijnen JH; Huitema AD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Mar; 919-920():43-51. PubMed ID: 23411018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS.
    Zheng JH; Guida LA; Rower C; Castillo-Mancilla J; Meditz A; Klein B; Kerr BJ; Langness J; Bushman L; Kiser J; Anderson PL
    J Pharm Biomed Anal; 2014 Jan; 88():144-51. PubMed ID: 24055850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma.
    Bennetto-Hood C; Long MC; Acosta EP
    Rapid Commun Mass Spectrom; 2007; 21(13):2087-94. PubMed ID: 17546653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A LC-MS method to quantify tenofovir urinary concentrations in treated patients.
    Simiele M; Carcieri C; De Nicolò A; Ariaudo A; Sciandra M; Calcagno A; Bonora S; Di Perri G; D'Avolio A
    J Pharm Biomed Anal; 2015 Oct; 114():8-11. PubMed ID: 25997174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of an LC/MS/MS method for the determination of tenofovir in monkey plasma.
    Guo J; Meng F; Li L; Zhong B; Zhao Y
    Biol Pharm Bull; 2011; 34(6):877-82. PubMed ID: 21628887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.
    Ocque AJ; Hagler CE; Morse GD; Letendre SL; Ma Q
    J Pharm Biomed Anal; 2018 Jul; 156():163-169. PubMed ID: 29709783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
    Schauer AP; Sykes C; Cottrell ML; Prince H; Kashuba ADM
    J Pharm Biomed Anal; 2018 Feb; 149():40-45. PubMed ID: 29100029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.
    Waitt C; Diliiy Penchala S; Olagunju A; Amara A; Else L; Lamorde M; Khoo S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():300-307. PubMed ID: 28651173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
    Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
    HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
    Hirt D; Urien S; Rey E; Arrivé E; Ekouévi DK; Coffié P; Leang SK; Lalsab S; Avit D; Nerrienet E; McIntyre J; Blanche S; Dabis F; Tréluyer JM
    Antimicrob Agents Chemother; 2009 Mar; 53(3):1067-73. PubMed ID: 19104016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
    Calcagno A; Gonzalez de Requena D; Simiele M; D'Avolio A; Tettoni MC; Salassa B; Orofino G; Bramato C; Libanore V; Motta I; Bigliano P; Orsucci E; Di Perri G; Bonora S
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1840-3. PubMed ID: 23380733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.